Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal.
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Part one of a three-part series.
The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
Awakn Life Sciences Corp.
Psyched: Psychedelic Therapy In The Workplace, UCL’s Brain Imaging Study, COMPASS Trials And More
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Mydecine Innovations Group Inc.
Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
Psychedelic therapeutics biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed three additional U.S.
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder.
Colorado’s Psychedelics Legal Scenario: Insurance & State Aid, Advisory Board And Local Regulations
Part three of three-part series.
See previous stories:
Colorado's New Psychedelics Regulations: Co-Author Of The Bill Replies To Concerns
Mental Health Clinic Poised To Become Leader In A Projected $50B Industry, Analyst Says
Irwin Naturals Inc. (OTCQB: IWINF) reported Tuesday a 7% year-over-year decline in revenue to $22 million for the third quarter of 2022.
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
(Part four of a four-part series)
See previous stories: